ES2626672T3 - Uso de ligandos sigma en dolor por cáncer de huesos - Google Patents

Uso de ligandos sigma en dolor por cáncer de huesos Download PDF

Info

Publication number
ES2626672T3
ES2626672T3 ES11794082.5T ES11794082T ES2626672T3 ES 2626672 T3 ES2626672 T3 ES 2626672T3 ES 11794082 T ES11794082 T ES 11794082T ES 2626672 T3 ES2626672 T3 ES 2626672T3
Authority
ES
Spain
Prior art keywords
hcl
ethyl
methyl
hydrochloride
dichlorophenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES11794082.5T
Other languages
English (en)
Spanish (es)
Inventor
Daniel Zamanillo-Castanedo
José Miguel Vela-Hernández
Carlos Plata-Salaman
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Pharmaceuticals SA
Original Assignee
Laboratorios del Dr Esteve SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratorios del Dr Esteve SA filed Critical Laboratorios del Dr Esteve SA
Application granted granted Critical
Publication of ES2626672T3 publication Critical patent/ES2626672T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4152—1,2-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. antipyrine, phenylbutazone, sulfinpyrazone
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • C07D231/20—One oxygen atom attached in position 3 or 5
    • C07D231/22—One oxygen atom attached in position 3 or 5 with aryl radicals attached to ring nitrogen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A61K31/4155—1,2-Diazoles non condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Emergency Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compression, Expansion, Code Conversion, And Decoders (AREA)
  • Steroid Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
ES11794082.5T 2010-12-03 2011-12-02 Uso de ligandos sigma en dolor por cáncer de huesos Active ES2626672T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP10382330 2010-12-03
EP10382330A EP2460519A1 (en) 2010-12-03 2010-12-03 Use of sigma ligands in bone cancer pain
PCT/EP2011/071584 WO2012072782A1 (en) 2010-12-03 2011-12-02 Use of sigma ligands in bone cancer pain

Publications (1)

Publication Number Publication Date
ES2626672T3 true ES2626672T3 (es) 2017-07-25

Family

ID=43629676

Family Applications (1)

Application Number Title Priority Date Filing Date
ES11794082.5T Active ES2626672T3 (es) 2010-12-03 2011-12-02 Uso de ligandos sigma en dolor por cáncer de huesos

Country Status (35)

Country Link
US (1) US20130324535A1 (enExample)
EP (2) EP2460519A1 (enExample)
JP (1) JP6027014B2 (enExample)
KR (1) KR101855358B1 (enExample)
CN (1) CN103313709B (enExample)
AR (1) AR084730A1 (enExample)
BR (1) BR112013013369A8 (enExample)
CA (1) CA2819442C (enExample)
CO (1) CO6781549A2 (enExample)
CY (1) CY1119030T1 (enExample)
DK (1) DK2646025T3 (enExample)
ES (1) ES2626672T3 (enExample)
HR (1) HRP20170818T1 (enExample)
HU (1) HUE033488T2 (enExample)
IL (1) IL226706A (enExample)
LT (1) LT2646025T (enExample)
MA (1) MA34878B1 (enExample)
ME (1) ME02852B (enExample)
MX (1) MX343773B (enExample)
MY (1) MY171994A (enExample)
NZ (1) NZ612119A (enExample)
PH (1) PH12013501127A1 (enExample)
PL (1) PL2646025T3 (enExample)
PT (1) PT2646025T (enExample)
RS (1) RS56081B1 (enExample)
RU (1) RU2585095C2 (enExample)
SG (1) SG190745A1 (enExample)
SI (1) SI2646025T1 (enExample)
SM (1) SMT201700270T1 (enExample)
TN (1) TN2013000227A1 (enExample)
TR (1) TR201708567T4 (enExample)
TW (1) TWI629060B (enExample)
UA (1) UA112638C2 (enExample)
WO (1) WO2012072782A1 (enExample)
ZA (1) ZA201304966B (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2116539A1 (en) 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof
EP2353598A1 (en) 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for use in the prevention and/or treatment of postoperative pain
EP2388005A1 (en) 2010-05-21 2011-11-23 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for the prevention and/or treatment of emesis induced by chemotherapy or radiotherapy
EP2415471A1 (en) 2010-08-03 2012-02-08 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in opioid-induced hyperalgesia
EP2426111A1 (en) * 2010-08-09 2012-03-07 Laboratorios Del. Dr. Esteve, S.A. 4-[-2-[[5-methyl-1-(2-naphtalenyl)-1h-pyrazol-3-yl]oxy]ethyl]morpholine hydrochloride amorphous solid forms
EP2524694A1 (en) 2011-05-19 2012-11-21 Laboratorios Del. Dr. Esteve, S.A. Use of sigma ligands in diabetes type-2 associated pain
EP2792352A1 (en) 2013-04-16 2014-10-22 Laboratorios Del. Dr. Esteve, S.A. Alpha-2 adrenoreceptor and sigma receptor ligand combinations
EP2818166A1 (en) * 2013-06-26 2014-12-31 Laboratorios del Dr. Esteve S.A. Use of sigma receptor ligands for the prevention and treatment of pain associated to interstitial cystitis/bladder pain syndrome (IC/BPS)
AR100021A1 (es) * 2013-09-12 2016-09-07 Esteve Labor Dr Combinaciones de ligando de receptores sigma y aine
AU2014364647A1 (en) 2013-12-17 2016-06-23 Laboratorios Del Dr. Esteve, S.A. Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) and Sigma receptor ligands combinations
AU2014364644A1 (en) 2013-12-17 2016-06-23 Laboratorios Del Dr. Esteve, S.A. Gabapentinoids and Sigma receptor ligands combinations
EP2929883A1 (en) * 2014-04-08 2015-10-14 Institut Pasteur Pyrazole derivatives as dihydroorotate dehydrogenase (DHODH) inhibitors
AR109024A1 (es) * 2016-07-12 2018-10-17 Esteve Labor Dr Uso de ligandos del receptor sigma en el dolor post-herpético
EP3415143A1 (en) * 2017-06-16 2018-12-19 Kai-Uwe Kern Bromhexine for the treatment of pain
WO2019224184A1 (en) * 2018-05-21 2019-11-28 Ipsen Biopharm Limited Suppression of bone cancer-induced allodynia
EP3886854A4 (en) 2018-11-30 2022-07-06 Nuvation Bio Inc. Pyrrole and pyrazole compounds and methods of use thereof
CN112341397B (zh) * 2019-08-09 2023-05-23 成都苑东生物制药股份有限公司 吡嗪类衍生物或盐、异构体、其制备方法及用途
KR102744822B1 (ko) 2020-06-05 2024-12-20 주식회사 허밍아비스 발열체 조성물 및 이를 이용한 마스크 제조방법

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1832928B (zh) * 2003-06-26 2012-07-04 诺瓦提斯公司 以5元杂环为基础的p38激酶抑制剂
EP2325174A1 (en) 2004-08-27 2011-05-25 Laboratorios Del. Dr. Esteve, S.A. Sigma receptor inhibitors
RU2417987C2 (ru) * 2004-08-27 2011-05-10 Лабораторьос Дель Др.Эстеве, С.А. Ингибиторы сигма-рецептора
US8202872B2 (en) * 2006-03-01 2012-06-19 Laboratorios Del Dr. Esteve, S.A. Pyrazole derivatives as sigma receptor inhibitors
EP2113501A1 (en) * 2008-04-25 2009-11-04 Laboratorios Del. Dr. Esteve, S.A. 5-Methyl-1-(naphthalen-2-YL)-1H-Pyrazoles useful as sigma receptor inhibitors
EP2116539A1 (en) * 2008-04-25 2009-11-11 Laboratorios Del. Dr. Esteve, S.A. 1-aryl-3-aminoalkoxy-pyrazoles as sigma ligands enhancing analgesic effects of opioids and attenuating the dependency thereof
EP2353591A1 (en) * 2010-02-04 2011-08-10 Laboratorios Del. Dr. Esteve, S.A. Sigma ligands for potentiating the analgesic effect of opioids and opiates in post-operative pain and attenuating the dependency thereof

Also Published As

Publication number Publication date
MA34878B1 (fr) 2014-02-01
MY171994A (en) 2019-11-11
SMT201700270T1 (it) 2017-07-18
HUE033488T2 (en) 2017-12-28
EP2646025B1 (en) 2017-03-15
SI2646025T1 (sl) 2017-07-31
TW201249805A (en) 2012-12-16
EP2460519A1 (en) 2012-06-06
SG190745A1 (en) 2013-07-31
PL2646025T3 (pl) 2017-09-29
AR084730A1 (es) 2013-06-05
BR112013013369A8 (pt) 2018-01-09
CO6781549A2 (es) 2013-10-31
LT2646025T (lt) 2017-06-12
PH12013501127A1 (en) 2020-10-19
AU2011334880B2 (en) 2016-09-15
ME02852B (me) 2018-04-20
CY1119030T1 (el) 2018-01-10
CN103313709A (zh) 2013-09-18
IL226706A (en) 2015-07-30
EP2646025A1 (en) 2013-10-09
TN2013000227A1 (en) 2014-11-10
WO2012072782A1 (en) 2012-06-07
HRP20170818T1 (hr) 2017-08-25
CA2819442A1 (en) 2012-06-07
ZA201304966B (en) 2014-09-25
NZ612119A (en) 2014-06-27
MX2013006140A (es) 2013-07-03
UA112638C2 (uk) 2016-10-10
RU2013130222A (ru) 2015-01-10
US20130324535A1 (en) 2013-12-05
TR201708567T4 (tr) 2019-01-21
JP2014501732A (ja) 2014-01-23
KR20130135881A (ko) 2013-12-11
BR112013013369A2 (pt) 2016-09-06
PT2646025T (pt) 2017-06-26
DK2646025T3 (en) 2017-06-06
KR101855358B1 (ko) 2018-05-04
TWI629060B (zh) 2018-07-11
CA2819442C (en) 2018-06-12
RS56081B1 (sr) 2017-10-31
AU2011334880A1 (en) 2013-07-11
RU2585095C2 (ru) 2016-05-27
MX343773B (es) 2016-11-23
CN103313709B (zh) 2017-05-24
JP6027014B2 (ja) 2016-11-16

Similar Documents

Publication Publication Date Title
ES2626672T3 (es) Uso de ligandos sigma en dolor por cáncer de huesos
ES2576844T3 (es) Ligandos sigma para uso para la prevención y/o el tratamiento de dolor postoperatorio
ES2673729T3 (es) Uso de ligandos sigma en la hiperalgesia inducida por opioides
ES2573715T3 (es) Ligandos sigma para la prevención y/o el tratamiento del vómito inducido por la quimioterapia o la radioterapia
US20160058771A1 (en) Alpha-2 adrenoceptor and sigma receptor ligand combinations
CN1988896A (zh) 采用σ受体上活性化合物治疗机械性痛觉超敏
US20090042898A1 (en) Use of compounds active on the sigma receptor for the treatment of mecanical allodynia
AU2011334880B9 (en) Use of sigma ligands in bone cancer pain
HK1190072B (en) Use of sigma ligands in bone cancer pain
HK1190072A (en) Use of sigma ligands in bone cancer pain
HK1179511B (en) Sigma ligands for use in the prevention and/or treatment of postoperative pain
TW201532605A (zh) α－２腎上腺素受體及σ受體配體組合